Carmot Therapeutics, Inc.

20 articles about Carmot Therapeutics, Inc.

• 

  Playing in the Hot Obesity Market, Carmot Braves Chilly IPO Waters

  11/20/2023

  Armed with a pipeline of obesity and diabetes hopefuls, Carmot Therapeutics joins the small group of biotechs to attempt a Nasdaq debut this year.

• Carmot Therapeutics Appoints Charles W. Newton to Board of Directors

  7/19/2023

  Carmot Therapeutics, Inc. today announced that it has appointed Charles “Charlie” Newton to its Board of Directors.

• Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions

  6/24/2023

  Carmot Therapeutics, Inc. announced positive results from the following studies: a Phase 1 clinical trial of CT-388 assessing safety, tolerability, pharmacokinetics and pharmacodynamic activity in overweight and obese otherwise healthy participants and a preclinical study in rodent models of type 1 diabetes to support the effects of CT-868 as an adjunct to insulin treatment.

• Carmot Therapeutics Appoints Michael Gray as Chief Financial Officer and Chief Operating Officer

  6/6/2023

  Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, is pleased to announce the appointment of Michael Gray as both Chief Operating Officer (COO) and Chief Financial Officer (CFO).

• Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes

  5/25/2023

  Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, announced a $150 million oversubscribed and up-sized Series E financing.

• Carmot Therapeutics to Present Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions

  5/23/2023

  Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, announced multiple presentations to take place at the American Diabetes Association Annual Meeting from June 23–26, 2023 in San Diego, CA.

• Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease

  1/5/2023

  Carmot Therapeutics, Inc. today announced its intent to spin off its Chemotype Evolution (CE) discovery platform in the fields of oncology, immunology and inflammation, to a separate and new company, Kimia Therapeutics (Kimia).

• Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COO

  9/21/2022

  Carmot Therapeutics, Inc. announced today an expansion of its Board of Directors and executive leadership team.

• 

  Philanthropic Donations and Debt Financings Rake in Cash for Cancer, Alzheimer's and Mental Healt...

  7/29/2022

  Money on the Move: ​​​​​​​A weekly roundup of notable funding news across biopharma industry. See who raked in funds for which diseases

• Carmot Therapeutics closes $160 million Series D financing to advance clinical pipeline of novel incretin receptor modulators

  7/26/2022

  Carmot Therapeutics, Inc., a clinical-stage biotechnology company applying its proprietary drug discovery platform, Chemotype Evolution, to discover and develop disease-modifying therapies in metabolic disease and cancer, announced today a $160 million Series D financing.

• Carmot Therapeutics Initiates Phase 1 Trial to Treat Type 2 Diabetes

  12/19/2018

  Carmot Therapeutics announced today the initiation of a clinical trial for the treatment of type 2 diabetes with CT-868, a dual modulator of the GLP-1 and GIP incretin receptors.

• Carmot Therapeutics Announces Close of Series B Financing

  1/17/2018

  Carmot announced today that it has closed a $15M financing.

• 

  Gilead Doubles Down on CAR-T

  12/12/2017

  Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its "Throttle" technology.
• 

  Bay Area's Carmot Lands $240M+ R&D Tie-Up With Biotech Giant Amgen

  12/6/2017

  Under the deal, Carmot will use its lead-identification technology to identify and advance novel drug leads for Parkinson's disease and other disease areas.

• Carmot Therapeutics, Inc. Appoints Aetna Wun Trombley, Ph.D. To The Board Of Directors And Elena Viboch As Director Of Business Development And Operations

  8/16/2016

• Carmot Therapeutics, Inc. Enters Into Discovery Collaboration With Genentech

  7/6/2016

• Carmot Therapeutics, Inc. Extends Drug Discovery Collaboration With Amgen

  2/16/2016

• Carmot Therapeutics, Inc. Strengthens Executive Management Team

  6/12/2014

• Carmot Therapeutics, Inc. Strengthens Executive Management Team

  6/11/2014

• Carmot Therapeutics, Inc. Enters Into Drug Discovery Collaboration With Amgen

  1/14/2014